Szymanska Edyta, Szymanska Sylwia, Dadalski Maciej, Kierkus Jaroslaw
Department of Gastroenterology, Hepatology, Feeding Disorders, and Paediatrics, The Children's Memorial Health Institute, Warsaw, Poland.
Prz Gastroenterol. 2023;18(2):141-147. doi: 10.5114/pg.2023.129412. Epub 2023 Jul 27.
Inflammatory bowel diseases (IBD) are chronic intestinal conditions of multifactorial aetiology including genetic susceptibility, immunological impairment, dysbiosis, and environmental factors. The diagnosis is based on both clinical and endoscopic features, wherein histopathological evaluation remains a gold diagnostic standard. However, fast, reliable, and non-invasive biological markers have been used for years for diagnosis as well as for disease activity monitoring. Currently, commonly used faecal calprotectin is the only biomarker approved and recommended by the European Crohn's and Colitis Organization (ECCO). Nonetheless, other biological markers discriminating between functional and organic bowel conditions have been widely studied. Therefore, the aim of this manuscript was to review new potential biomarkers of inflammation in IBD. The aim of this study was to review currently available biomarkers of intestinal inflammation and increased gut permeability in IBD.
炎症性肠病（IBD）是一种多因素病因的慢性肠道疾病，包括遗传易感性、免疫功能损害、肠道菌群失调和环境因素。诊断基于临床和内镜特征，其中组织病理学评估仍然是金标准诊断方法。然而，快速、可靠且非侵入性的生物标志物多年来一直用于诊断以及疾病活动监测。目前，常用的粪便钙卫蛋白是欧洲克罗恩病和结肠炎组织（ECCO）批准并推荐的唯一生物标志物。尽管如此，其他区分功能性和器质性肠道疾病的生物标志物也得到了广泛研究。因此，本手稿的目的是综述IBD炎症的新潜在生物标志物。本研究的目的是综述IBD中目前可用的肠道炎症和肠道通透性增加的生物标志物。
